GSK's Lost Quarter: $3 Billion DoJ Settlement Far Outstrips Net Profit
This article was originally published in The Pink Sheet Daily
Executive Summary
If approved, the settlement would set a new record for the pharmaceutical industry in its dealings with the federal government, but would be covered by the firm's existing reserves.